One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

Disclosed herein are compounds, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and/or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

Disclosed herein are compounds, combinations, and kits that can be used to more quickly remove radionuclides from a subject, preferably a human being. Said compounds, combinations and kits can also be used to increase the tumor-to-blood ratio, or to more rapidly and/or conveniently achieve such an increase, of a label in targeted imaging or targeted radiotherapy in a subject, preferably a human being.

The invention relates to innovative, water-dispersible, hydrophilic polyisocyanates and polyisocyanate mixtures, to a process for preparing them, to compositions comprising the hydrophilic polyisocyanates of the invention, and to their use as a starting component in the production of polyurethane plastics, more particularly as crosslinkers for water-soluble or water-dispersible film-forming, adhesives or sealant binders or binder components having groups which are reactive towards isocyanate groups.

The invention relates to innovative, water-dispersible, hydrophilic polyisocyanates and polyisocyanate mixtures, to a process for preparing them, to compositions comprising the hydrophilic polyisocyanates of the invention, and to their use as a starting component in the production of polyurethane plastics, more particularly as crosslinkers for water-soluble or water-dispersible film-forming, adhesives or sealant binders or binder components having groups which are reactive towards isocyanate groups.

Disclosed herein is a method for analyzing the concentration of a fluorescent compound in the plasma of a patient. The method includes collecting a sample of plasma from a patient, diluting the sample with a solvent and analyzing the diluted sample by HPLC. The sample does not need to be dried down during sample preparation nor is an internal standard required.

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.

One aspect of the disclosure relates to the use of derivatives of dichlorophenyl urea for treating cancers.